Adjuvant Letrozole Femara vs Placebo in Women With Primary Breast Cancer Completing 5 Years of Tamoxifen

Background. 500 000 postmenopausal new breast cancers worldwide annually> 50 % of recurrences occur beyond 5 years of diagnosisTamoxifen reduces recurrences profoundly BUT disappointingly adds no benefit if given for > 5 yearsWe set out to test whether another type of hormone therapy, letrozole,

gasha + Follow